ImmunoPET Targeting Receptor Tyrosine Kinase: Clinical Applications

被引:2
|
作者
Linguanti, Flavia [1 ,2 ]
Abenavoli, Elisabetta Maria [3 ]
Calabretta, Raffaella [4 ]
Berti, Valentina [1 ]
Lopci, Egesta [5 ]
机构
[1] Univ Florence, Dept Expt & Clin Biomed Sci Mario Serio, Nucl Med Unit, I-50134 Florence, Italy
[2] Osped San Donato, Nucl Med Dept, I-52100 Arezzo, Italy
[3] Careggi Univ Hosp, Nucl Med Div, I-50134 Florence, Italy
[4] Med Univ Vienna, Dept Biomed Imaging & Image Guided Therapy, Div Nucl Med, A-1090 Vienna, Austria
[5] IRCCS Humanitas Res Hosp, Nucl Med Unit, Via Manzoni 56, I-20089 Rozzano, Italy
关键词
ImmunoPET; PET/CT; receptor tyrosine kinases; RTK; EGFR; HER2; HER3; VEGF; METASTATIC BREAST-CANCER; ZIRCONIUM-89 LABELED CETUXIMAB; GROWTH-FACTOR RECEPTOR-3; PHASE-I; CU-64-DOTA-TRASTUZUMAB PET; ZR-89-BEVACIZUMAB PET; TRASTUZUMAB EMTANSINE; CELL CARCINOMA; HER3; RECEPTOR; EXPRESSION;
D O I
10.3390/cancers15245886
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Receptor tyrosine kinases (RTKs) are a family of transmembrane proteins that play crucial roles in regulating various cellular processes. The introduction of ImmunoPET targeting RTKs by specific monoclonal antibodies (mAbs) or antibody fragments is regarded as a promising tool for imaging treatment efficacy and developing anticancer drugs. Herein, we review the current clinical research on ImmunoPET targeting RTKs, with particular interest in the epidermal growth factor family, or HER family, and vascular endothelial-derived growth factor/receptor.Abstract Receptor tyrosine kinases, or RTKs, are one large family of cell surface receptors involved in signal transduction, which represent an integral part of the signaling pathways. They play a crucial role in most important cellular processes, starting with the cell cycle, proliferation and differentiation, as well as cell migration, metabolism and survival. The introduction of ImmunoPET evaluating the expression of RTKs by specific monoclonal antibodies (mAbs) or antibody fragments is regarded as a promising tool for imaging treatment efficacy and developing anticancer therapeutics. Our review focuses mainly on the current clinical research regarding ImmunoPET targeting RTKs, with particular interest in the epidermal growth factor family, or HER family, and vascular endothelial-derived growth factor/receptor.
引用
收藏
页数:23
相关论文
共 50 条
  • [41] Targeting receptor tyrosine kinase signaling: Avenues in the management of cutaneous squamous cell carcinoma
    Pillai, Mohan Shankar Gopinatha
    Aiswarya, Sreekumar U.
    Keerthana, Chenicheri K.
    Rayginia, Tennyson P.
    Anto, Ruby John
    ISCIENCE, 2023, 26 (06)
  • [42] Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation
    Jiao, Yisheng
    Ou, Wenbin
    Meng, Fanguo
    Zhou, Haimeng
    Wang, Aiyuan
    MOLECULAR CANCER, 2011, 10
  • [43] Combinatorial Targeting of the c-KIT Receptor Tyrosine Kinase in Acute Myeloid Leukemia
    Murray, Heather
    Enjeti, Anoop K.
    Kahl, Richard
    Flanagan, Hayley
    Verrills, Nikki
    Dun, Matthew
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 14 - 14
  • [44] Molecular Characterization and Therapeutic Targeting of Colorectal Cancers Harboring Receptor Tyrosine Kinase Fusions
    Singh, Harshabad
    Li, Yvonne Y.
    Spurr, Liam F.
    Shinagare, Atul B.
    Abhyankar, Ritika
    Reilly, Emma
    Brais, Lauren K.
    Nag, Anwesha
    Ducar, Matthew D.
    Thorner, Aaron R.
    Shapiro, Geoffrey, I
    Keller, Rachel B.
    Siletti, Cheta
    Clark, Jeffrey W.
    Farago, Anna F.
    Lin, Jessica J.
    Demetri, George D.
    Gujrathi, Rahul
    Kulke, Matthew H.
    MacConaill, Laura E.
    Ligon, Azra H.
    Sicinska, Ewa
    Meyerson, Matthew L.
    Meyerhardt, Jeffrey A.
    Cherniack, Andrew D.
    Wolpin, Brian M.
    Ng, Kimmie
    Giannakis, Marios
    Hornick, Jason L.
    Cleary, James M.
    CLINICAL CANCER RESEARCH, 2021, 27 (06) : 1695 - 1705
  • [45] Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment
    Smith, Eric A.
    Belote, Rachel L.
    Cruz, Nelly M.
    Moustafa, Tarek E.
    Becker, Carly A.
    Jiang, Amanda
    Alizada, Shukran
    Prokofyeva, Anastasia
    Chan, Tsz Yin
    Seasor, Tori A.
    Balatico, Michael
    Cortes-Sanchez, Emilio
    Lum, David H.
    Hyngstrom, John R.
    Zeng, Hanlin
    Deacon, Dekker C.
    Grossmann, Allie H.
    White, Richard M.
    Zangle, Thomas A.
    Judson-Torres, Robert L.
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2024, 43 (01)
  • [46] A novel small peptide as a targeting ligand for receptor tyrosine kinase Tie2
    Wu, XH
    Zhao, RJ
    Li, ZH
    Yao, M
    Wang, HM
    Han, JS
    Qu, SM
    Chen, XL
    Qian, LF
    Sun, Y
    Xu, YH
    Gu, JR
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 315 (04) : 1004 - 1010
  • [47] Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 (‘Iressa’)
    J M Sewell
    K G Macleod
    A Ritchie
    J F Smyth
    S P Langdon
    British Journal of Cancer, 2002, 86 : 456 - 462
  • [48] Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulation
    Leiser, Dominic
    Pochon, Benoit
    Blank-Liss, Wieslawa
    Francica, Paola
    Glueck, Astrid A.
    Aebersold, Daniel M.
    Zimmer, Yitzhak
    Medova, Michaela
    FEBS LETTERS, 2014, 588 (05): : 653 - 658
  • [49] DIFFERENTLY SPLICED CDNAS OF HUMAN-LEUKOCYTE TYROSINE KINASE RECEPTOR TYROSINE KINASE PREDICT RECEPTOR PROTEINS WITH AND WITHOUT A TYROSINE KINASE DOMAIN AND A SOLUBLE RECEPTOR PROTEIN
    TOYOSHIMA, H
    KOZUTSUMI, H
    MARU, Y
    HAGIWARA, K
    FURUYA, A
    MIOH, H
    HANAI, N
    TAKAKU, F
    YAZAKI, Y
    HIRAI, H
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (12) : 5404 - 5408
  • [50] Targeting neurotrophin-3 and its dependence receptor tyrosine kinase receptor C: a new antitumoral strategy
    Tauszig-Delamasure, Servane
    Bouzas-Rodriguez, Jimena
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2011, 15 (07) : 847 - 858